TITLE

ARCHIMEDES PHARMA BEGINS PHASE III FOR NASALFENT

PUB. DATE
March 2007
SOURCE
Worldwide Biotech;Mar2007, Vol. 19 Issue 3, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that European specialty pharmaceutical company Archimedes Pharma Ltd. has announced the commencement of its global Phase III programme for Nasalfent (r) in breakthrough cancer pain. Patients are being recruited in a placebo controlled, randomised trial in the U.S. and Canada. The efficacy of Nasalfent, which contains fentanyl, a claimed effective opiate analgesic is discussed. Archimedes' proprietary PecSys nasal drug delivery system is incorporated in Nasalfent.
ACCESSION #
24159816

 

Related Articles

  • Archimedes Breakthrough Pain Drug Gets Pain-Free REMS. Serebrov, Mari; Moran, Nuala // BioWorld Today;7/6/2011, Vol. 22 Issue 129, p1 

    The article reports on the approval received by Archimedes Pharma Ltd. from the U.S. Food and Drug Administration (FDA) for its fentanyl drug Lazanda. It notes that Lazanda's pain-free risk evaluation and mitigation strategy (REMS) and intranasal delivery could give it a competitive advantage...

  • Archimedes Breakthrough Pain Drug Gets Pain-Free REMS. Moran, Nuala // BioWorld International;7/6/2011, Vol. 16 Issue 27, p1 

    The article reports on the effort of Archimedes Pharma Ltd. to create its U.S. operations, winning an approval from the U.S. Food and Drug Administration (FDA) for Lazanda, the nasally delivered formulation of the anesthetic fentanyl, in the treatment of cancer pain. The formulation is...

  • LAZANDA.  // MPR - Pharmacist's Edition;Winter2011/2012, Vol. 5 Issue 4, pA:5 

    The article offers brief information on Lazanda fentanyl intranasal transmucosal spray for patient with opioid tolerance from Archimedes Pharma Ltd.

  • Spray improved pain management in cancer patients.  // Hem/Onc Today;5/25/2013, Vol. 14 Issue 10, p56 

    The article discusses the findings of a randomized study which revealed the therapeutic use of fentanyl sublingual spray in improving a number of pain and adverse event categories in a cohort of patients with several types of cancer.

  • Regulatory Update.  // PharmaWatch: CNS;Oct2010, Vol. 9 Issue 10, p18 

    The article focuses on the announcement of Archimedes Pharma Ltd., a specialty pharmaceutical company, that the European Commission has granted marketing authorization for its lead product, PecFent, a nasal spray for cancer pain in adults.

  • OTHER NEWS TO NOTE.  // BioWorld International;10/15/2008, Vol. 13 Issue 42, p2 

    This section offers news briefs on the biotechnology industries. Antisoma plc acquired the rights to develop and commercialize anticancer protein phosphatase magnesium-dependent 1 d (PPM1D) inhibitors from the Institute of Cancer Research. Archimedes Pharma Ltd. reported positive Phase III...

  • Other News To Note.  // BioWorld International;9/8/2010, Vol. 15 Issue 35, p3 

    This section offers news briefs on the biotechnology industry. Addex Pharmaceuticals Ltd. will start phase I trial on preclinical efficacy of a candidate drug on Alzheimer's disease that inhibits the metabotropic glutamate receptor 2 (mGluR2). Agennix AG has completed Phase II trial of...

  • SURVIVAL ANALYSIS FROM SATRAPLATIN TRIAL DISAPPOINTING.  // Worldwide Biotech;Dec2007, Vol. 19 Issue 12, p8 

    The article reports that topline overall survival results for the double-blinded, randomized satraplatin Phase 3 registrational trial, the Satraplatin and Prednisone Against Refractory Cancer (SPARC) trial, has been announced by GPC Biotech AG and PharmionCorporation. The trial evaluated...

  • Re: Racial Disparities in Cancer Survival Among Randomized Clinical Trials of the Southwest Oncology Group. GRAVLEE, CLARENCE C.; MULLIGAN, CONNIE J. // JNCI: Journal of the National Cancer Institute;2/24/2010, Vol. 102 Issue 4, p280 

    This section presents comments on the article "Racial Disparities in Cancer Survival Among Randomized Clinical Trials of the Southwest Oncology Group," by Albain et al. The authors claim that the speculations made by Albain et al. about genetic differences go beyond the data and neglect...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics